Sepsis treatment options identified by 10-year study of microbial isolates and antibiotic susceptibility in a level-four neonatal intensive care unit
Autor: | Arild Rønnestad, Anne Lee Solevåg, Jørgen Vildershøj Bjørnholt, Hans Jørgen Stensvold, Eline Hasselgård Størdal |
---|---|
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
Neonatal intensive care unit Cefotaxime Microbial Sensitivity Tests Cloxacillin Vancomycin Ampicillin Internal medicine Intensive Care Units Neonatal Sepsis medicine Humans Blood culture Neonatal sepsis medicine.diagnostic_test business.industry Infant Newborn Infant General Medicine medicine.disease Anti-Bacterial Agents Pediatrics Perinatology and Child Health Gentamicin Gentamicins Neonatal Sepsis business medicine.drug |
Zdroj: | Acta paediatrica (Oslo, Norway : 1992)REFERENCES. 111(3) |
ISSN: | 1651-2227 0803-5253 |
Popis: | Aim This observational study investigated the microbiology of blood culture positive sepsis episodes and susceptibility to empiric antibiotics in early-onset sepsis (EOS) and late-onset sepsis (LOS) in a level four neonatal intensive care unit (NICU) from 2010-2019. Methods It was based on patient records and data that Oslo University Hospital, Norway, routinely submitted to the Norwegian Neonatal Network database. Clinical data were merged with blood culture results, including antibiotic susceptibility. Results We studied 5,249 infants admitted to the NICU 6,321 times and identified 324 positive blood cultures from 287 infants, with 30 EOS and 305 LOS episodes. Frequent causative agents for EOS were group B streptococci (33.3%), Escherichia coli (20.0%) and Staphylococcus aureus (16.7%). All were susceptible to empiric ampicillin and gentamicin. LOS was most frequently caused by coagulase-negative staphylococci (CONS) (73.8%), Staphylococcus aureus (15.7%) and Enterococci (6.9%). CONS, Staphylococcus aureus, Enterococci, Escherichia coli, Klebsiella and Enterobacter represented 91.9% of LOS episodes and were susceptible to vancomycin and cefotaxime (96.1%), vancomycin and gentamicin (97.0%) and cloxacillin and gentamicin (38.1%). Conclusion Empiric treatment with ampicillin and gentamicin was adequate for EOS. Combining vancomycin and gentamicin may be a safer alternative to cefotaxime for LOS, as this reduces exposure to broad-spectrum antibiotics. |
Databáze: | OpenAIRE |
Externí odkaz: |